Amonafide in Combination With Cytarabine in Secondary AML

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

April 30, 2009

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Amonafide L-Malate

DRUG

Cytarabine

Trial Locations (21)

27157

Wake Forest University Health Sciences, Winston-Salem

27710

Duke University Medical Center, Durham

29425

MUSC - Hollings Cancer Center, Charleston

46202

St. Francis Cancer Research Foundation (formerly Indiana Oncology Hematology Consultants and American Health Network of Indiana LLC, Oncology Division), Indianapolis

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago

75246

Roswell Park Cancer Institute, Buffalo

Baylor University Medical Center, Dallas

80010

University of Colorado Health Sciences Center, Anschutz Cancer Center, Aurora

90024

UCLA Medical Center, Los Angeles

91010

City of Hope National Medical Center, Duarte

92121

Scripps Cancer Center, San Diego

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

32610-0277

University of Florida Health Science Center, Gainesville

02115

Dana Farber Cancer Institute, Boston

01655

University of Massachusetts Memorial Medical Center, Worcester

48109-0848

University of Michigan, Ann Arbor

98198 7835

University of Nebraska Medical Center, Omaha

26506-9162

West Virginia University Medical Center, Morgantown

V5Z 4E3

Vancouver General Hospital, Vancouver

N6A 4L6

London Regional Cancer Program, London Health Science Center, London

All Listed Sponsors
lead

Xanthus Pharmaceuticals, Inc.

INDUSTRY

NCT00273884 - Amonafide in Combination With Cytarabine in Secondary AML | Biotech Hunter | Biotech Hunter